Sugi Predict

Sugi Predict / Compounds / SCHEMBL319266

SCHEMBL319266

SCHEMBL319266

COc1ccc(CNc2ncccn2)c(OC)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 1/20 0.63
▸ CYP1A2 P05177 11/20 0.58
▸ CYP3A4 P08684 11/20 0.58
▸ CYP2D6 P10635 11/20 0.58
▸ CYP2C19 P33261 10/20 0.58
▸ TSHR P16473 9/20 0.58
▸ CLK4 Q9HAZ1 8/20 0.58
▸ LMNA P02545 6/20 0.58
▸ USP2 O75604 3/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ ALDH1A1 P00352 4/20 0.56
▸ MAPK1 P28482 4/20 0.56
▸ ALOX15 P16050 2/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ NPC1 O15118 1/20 0.55
▸ PKM P14618 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ CYP2C9 P11712 3/20 0.55
▸ GLA P06280 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29669157 0.85 L3MBTL1 (0.74) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL16109009 0.85 L3MBTL1 (0.74) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL20252526 0.84 GAA (0.51) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL319769 0.84 APLNR (0.58) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL24033844 0.83 CYP1A2 (0.55) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3451889 0.83 CYP1A2 (0.60) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL29581979 0.82 CYP1A2 (0.56) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
Potassium Ion SCHEMBL30041407 0.82 CYP1A2 (0.54) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL30080224 0.82 CYP1A2 (0.56) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
Potassium Ion SCHEMBL28907400 0.82 CYP1A2 (0.54) APLNRCYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110325531-B Benzenesulfonamides and their use as therapeutic agents 泽农医药公司 2022-05-27 — — CN disclosed
CN-108290881-B Therapeutic compounds and methods of use thereof 健泰科生物技术公司 2021-12-07 — — CN disclosed
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 — — US disclosed
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 — — US disclosed
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2021-06-10 — — US disclosed
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2021-06-10 — — US disclosed
US-20210171516-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-06-10 — — US disclosed
US-10787446-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2020-09-29 — — US disclosed
EP-3551626-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2019-10-16 — — EP disclosed
US-10316026-B2 Method for removing dimethoxybenzyl group DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-06-11 — — US disclosed
EP-2590951-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS Pfizer Limited (GB) 2013-05-15 — — EP disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 — — US disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 — — US disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 — — US disclosed
WO-2012004714-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed
WO-2012004714-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed
WO-2012004743-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed
WO-2012004743-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 — — US disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents KCND2, SCN1A, CACNA1D APLNR 3027/4885CYP1A2 831/4885CYP3A4 414/4885
US-20130109696-A1 Chemical Compounds SCN1A, SCN7A, SCN1B APLNR 2977/4885CYP1A2 291/4885CYP3A4 537/4885
US-20120010182-A1 Chemical Compounds SCN1A, SCN1B, CACNA1E APLNR 2516/4885CYP1A2 643/4885CYP3A4 849/4885
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B APLNR 3822/4885CYP1A2 926/4885CYP3A4 396/4885
US-10787446-B2 Therapeutic compounds and methods of use thereof AVPR1B, C3AR1, RHEB APLNR 497/4885CYP1A2 1915/4885CYP3A4 2526/4885
US-20210171516-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF AVPR1B, C3AR1, RHEB APLNR 497/4885CYP1A2 1915/4885CYP3A4 2526/4885
US-10316026-B2 Method for removing dimethoxybenzyl group DDT, ALKBH5, DDO APLNR 2548/4885CYP1A2 978/4885CYP3A4 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.